Alkaline phosphatases (APs) remove the phosphate (dephosphorylation) needed in multiple metabolic processes (from many molecules such as proteins, nucleotides, or pyrophosphate). Therefore, APs are important for bone mineralization but paradoxically they can also be deleterious for other processes, such as vascular calcification and the increasingly known cross-talk between bone and vessels. A proper balance between beneficial and harmful activities is further complicated in the context of chronic kidney disease (CKD). In this narrative review, we will briefly update the complexity of the enzyme, including its different isoforms such as the bone-specific alkaline phosphatase or the most recently discovered B1x. We will also analyze the correlations and potential discrepancies with parathyroid hormone and bone turnover and, most importantly, the valuable recent associations of AP's with cardiovascular disease and/or vascular calcification, and survival. Finally, a basic knowledge of the synthetic and degradation pathways of APs promises to open new therapeutic strategies for the treatment of the CKD-Mineral and Bone Disorder (CKD-MBD) in the near future, as well as for other processes such as sepsis, acute kidney injury, inflammation, endothelial dysfunction, metabolic syndrome or, in diabetes, cardiovascular complications. However, no studies have been done using APs as a primary therapeutic target for clinical outcomes, and therefore, AP's levels cannot yet be used alone as an isolated primary target in the treatment of CKD-MBD. Nonetheless, its diagnostic and prognostic potential should be underlined.
Introduction
Alkaline phosphatases (APs) are membrane-bound glycoprotein hydrolases responsible for removing phosphate (P) groups (dephosphorylation or P-ester hydrolysis) from many molecules (nucleotides, proteins…), most effectively operating in an alkaline environment [1] (Fig. 1 ). Thus, P becomes available for many processes not only such as bone mineralization but also, as we appreciated in recent years, vascular calcification. Circulating APs, particularly the tissue non-specific alkaline phosphatase (TNAP), may increase hydrolysis of pyrophosphate [2, 3] , a natural inhibitor of hydroxyapatite formation in the extracellular fluid. Indeed pyrophosphate, which physiologically comes from the hydrolysis of extracellular nucleotides (essentially ATP) by the enzyme ENPP1 (ectonucleotide pyrophosphatase phosphodiesterase type 1, to pyrophosphate and AMP) (Fig. 2) , is a well-known potent inhibitor of vascular calcification since it prevents the incorporation of inorganic P into hydroxyapatite crystals [1, 2, 4] . Consequently, the modulatory effect of APs on the balance between inorganic P and inorganic pyrophosphate seems to be involved in the increasingly recognized cross-talk between bone and vessels and the imbalance between bone mineralization and cardiovascular calcification . This narrative review will briefly update the biochemical complexity of the enzyme, the correlations with parathyroid hormone (PTH) and bone turnover, and the most recent associations with survival, vascular calcification, and cardiovascular disease. Knowledge of the synthetic and degradation pathways of this enzyme promises to open new therapeutic perspectives, even beyond chronic kidney disease-mineral and bone disorders (CKD-MBD). (VSMC) , from top to bottom: Apyrase1/ ectonucleoside triphosphatase diphosphohydrolase 1 (eNTPD1) is an important ectoenzyme for the synthesis of inorganic phosphate (P i ) from adenosine triphosphate (ATP). On this same substrate acts the ectoenzyme nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), but promoting the synthesis of pyrophosphate (PP i ), so that ATP is a substrate of both ectoenzymes. ATP comes from the intracellular space by the action of several transporters such as the transmembrane protein (Ank) which is the product expression of the ankylosis gene. High extracellular ATP levels are related with pathological calcification [165] . Tissue-nonspecific alkaline phosphatase (TNAP) hydrolyzes extracellular PP i to P i , which can then enter the VSMC by transporters Pit-1 and Pit-2. Once inside the cell, P i can be taken up by the mitochondria and form new ATP molecules through oxidative phosphorylation. However, higher concentrations of P i within the VSMC also promote cellular transformation to a bone-forming cell phenotype, overexpressing osteochondrogenic transcription markers. On the other hand, the P i that does not enter the cell increases the tissue deposits of calcium and P i promoting tissue calcification. Right side: Bone cells. Mineralization of hydroxyapatite (HA) seems to be initiated both by the accumulation of iP generated inside the cell by the action of Phospho-1 [phosphoethanolamine/phosphocholine (PC) phosphatase] and the P i transported from the extracellular space by Pit-1. Extracellular P i concentrations depend on the action of: (a) NPP1, which normally stimulates extracellular PP i synthesis but, under conditions of low expression of TNAP, promotes the synthesis of P i from both extracellular ATP and from PP i (like TNAP). (b) TNAP, which hydrolyzes both PP i and ATP to form P i . This P i can either enter bone cells for appropriate use or it can be in blood where it will maintain the PP i -P i ratio (one of the main determinants of vascular calcification and bone mineralization). As mentioned in the text, TNAP derives from several tissues and when refers to bone it is the bone-specific alkaline phosphatase (BSAP). Center: Central Nervous system (CNS). TNAP acts on Pyridoxal 5'-Phosphate (PLP). This is the major form of circulating vitamin B6 (metabolically active) and serves as a cofactor for at least 110 enzymes and as a coenzyme for the metabolism of several amino-acids (including those necessary for neurotransmitters (dopamine, serotonin, histamine, taurine and γ-aminobutyric acid). TNAP removes P i from the PLP molecule so that it becomes Pyridoxal (PL), one of the 7 forms of vitamin B6 and the only one that can enter in CNS cells, where PL is phosphorylated and converted back into PLP, becoming again the needed cofactor for a proper CNS functioning. Adapted from reference [161] Total Alkaline Phosphatases and Bone-Specific Alkaline Phosphatase Isoenzymes Total AP includes two types of isoenzymes: tissue-and TNAPs. Tissue-specific APs are encoded by 3 genes and they derive from intestine, placenta, and stem-cells [1, 10] , representing only about 5% of the total circulating APs. The TNAPs are encoded by a single gene and are present in several tissues, including liver, kidney, and bone, the last one referred to as bone-specific AP, BSAP, or BALP. Liver AP represents approximately 45% and BSAP 50% of total circulating APs but the exact mechanisms of AP release into the general circulation remain unclear.
BSAP is the generic term given to one of the enzymatic non-collagenous bone proteins [1] with a molecular weight of 80 kDa and a relatively long half-life of 1.5-2.3 days, although it is lower than liver's (5-9 days). BSAP is a glycoprotein anchored to the membrane of osteoblasts and, as a by-product of osteoblast activity, it became a renowned and very specific bone formation marker [(such as osteocalcin and opposed to the bone resorption marker tartrate-resistant acid phosphatase (TRAP)] which we will review later. BSAP can bind to bone matrix proteins and induce bone mineralization through stimulation of pyrophosphate hydrolysis [1] (Fig. 2) . BSAP isoforms may be distinguished by diverse posttranslational glycosylation type and extension, contributing to distinct catalytic properties [11] .
Relation Between Total APs, BSAP, PTH, and Bone Turnover
Total AP has classically been associated with bone formation and generally regarded as a reliable marker of bone turnover in CKD [12, 13] , provided that intact liver and biliary systems are present [1, 9] . Less known is that hypervolemia or diastolic dysfunction in CKD (mainly dialysis patients) may increase total AP, probably by subclinical liver congestion and therefore not representing bone formation activity [14] . Moreover, one cannot always assume that if other hepatic enzymes (such as gamma-glutamyltransferase) are normal, increased total AP is from bone; thus, it has also been described that intestinal AP may be increased in hemodialysis patients [15] [16] [17] [18] . Intestinal AP is an emerging field on clinical research as this AP isoenzyme has important functions in gut mucosal defense [19] . Total AP levels, as opposed to intact PTH (iPTH), are not affected by renal function [20] .
On the other hand, BSAP is superior to total AP since BSAP is more sensitive and specific for bone disease, especially given the previously mentioned possible interference with liver isoenzymes, therefore becoming the most important marker for osteoblast differentiation [20, 21] . Furthermore, BSAP distinguishes better than both iPTH and total APs clinical situations of normal/low-turnover-from high-turnover-bone disease in dialysis patients [21] . Thus, it has been reported that BSAP ≥ 20 ng/ml, alone or combined with iPTH of ≥ 200 pg/ml, had the highest sensitivity, specificity, and predictability values for the diagnosis of high-turnover bone disease and excluded patients with normal-or low-turnover-bone disease [20] . On the other side, several observations suggest that the diagnosis of lowturnover-bone disease in hemodialysis patients should be suspected when plasma iPTH levels are less than 150 pg/ ml and that BSAP levels are lower than 7 ng/ml (Ostase® method) [21, 22] . Coen et al. reported that, in 41 hemodialysis patients who underwent a bone biopsy, a plasma BSAP concentration lower than 12.9 ng/ml had a sensitivity of 100%, a specificity of 94%, and a positive predictive value of 72% in the prediction of low-turnover-bone disease [13] . Finally, in a recent prospective study of hemodialysis patients treated with calcimimetics with iPTH ≥ 300 pg/ ml (Advia Centaur) and BSAP > 20.9 ng/ml (Ostase®), no bone-biopsy-based evidence of high-turnover bone disease was found in 17% of patients (22 normal, 3 mixed lesions), and no adynamic bone disease was present under these conditions [23] . A posterior cross-sectional retrospective diagnostic study found that BSAP was able to discriminate both low-from non-low and high-from non-high-bone-turnover disease analyzing 492 dialysis patients from Brazil, Portugal, Turkey, and Venezuela with a prior bone biopsy but without consideration of therapy [24] . In this study, the best cutoff for BSAP to discriminate low-from non-low-bone-turnover disease was < 33.1 U/L and for high-from non-high-boneturnover disease was > 42.1 U/L [24] . Importantly, serum BSAP was the only serum marker significantly higher among 137 dialysis patients with distal radius bone mineral density (BMD) reduction, including the sub-analysis of 42 diabetic patients with serum iPTH < 180 pg/ml (hypothetically low-bone-turnover state) [25] . Therefore, BSAP also seems to be a clinically useful bone formation marker to predict BMD reduction at least in diabetic dialysis patients with low circulating iPTH levels. A brief summary of the predictive value of intact PTH and BSAP in CKD patients is presented in Table 1 .
Discrepancies Between Parathyroid and Bone Activities
Discrepancies between serum iPTH and BSAP levels, reflecting an uncoupling between bone resorption and formation, are uncommon but may be found in some patients [20, 26, 27] (Table 2) . Part of these discrepancies may be related to variability in the measurements of BSAP and iPTH. For instance, Delanaye et al. showed that there are large discrepancies in the variations of iPTH and BSAP concentrations over time in CKD-5D patients [28] . They also did not see any correlation between ΔiPTH and ΔBSAP over a 6-week interval [28] .
Increased serum iPTH levels with low BSAP may reflect different degrees of the well-known multifactorial skeletal resistance or decreased calcemic response to PTH (also called hypo-responsiveness to PTH), clearly described in CKD [29, 30] . Evanson reported it for the first time in 1996, when he noted that the calcemic response to an infusion of parathyroid extract was significantly lower in hypocalcemic patients with CKD compared with normal subjects or patients with primary hyperparathyroidism [31] . Subsequently, other authors extended these observations in patients with early CKD [32-34], confirming that a greater concentration of circulating PTH is required to maintain normal serum Ca levels in affected patients. In experimental conditions, when a fixed amount of PTH is infused into an experimental animal (i.e., subcutaneously through an Alzet pump), the calcemic response to PTH is also markedly decreased in animals with kidney disease as compared with sham controls [26, 27, 30, 35] (Fig. 3) .
Hyperphosphatemia, low calcitriol, increasing age, and uremia itself, among others, have been described as contributing factors to skeletal resistance to PTH in CKD [26, 30, [35] [36] [37] [38] . Moreover, down-regulation of osteoblastic PTH . As a matter of fact, uremia may thus be considered a disease which extensively affects different types of receptors (uremia as a "receptor disease") and discrepancies between iPTH and BSAP are possible (Table 1) . Additionally, iPTH is only indirectly associated with bone formation and represents much better the parathyroid activity than bone dynamics. This PTH hypo-responsiveness or resistance to PTH in CKD is also one of the reasons why a complete normalization of iPTH values in CKD patients should not be a treatment goal, due to this hypo-responsiveness and beyond the imprecision associated with the inappropriate detection of serum PTH fragments in CKD. Nevertheless, we do not know yet which is the adequate PTH goal associated with a normal bone formation rate or improved survival at every stage of CKD [51, 52] . In fact, we do not even know whether the target to optimize bone disease and survival end-points is equivalent. In any case, there is a generalized agreement on that low PTH levels (i.e., < 2x the upper limit of normality) are associated with adynamic bone disease (and its potential complications) in dialysis patients [51] [52] [53] . In this setting, the evaluation of APs and/or BSAP may especially provide clinical useful information about the actual bone status. Several circulating human BSAP isoforms have also recently been described [54] . They are distinguished by the variable amounts of sialic acid residues or glycosylation differences in the molecule [55, 56] , contributing to distinct catalytic properties [56] . Three circulating human BSAP isoforms [B1, B2, and Bone/intestine (B/I)] can be distinguished in healthy individuals. B/I and B2 isoforms are specially increased in CKD [57] . Moreover, a fourth isoform that only circulates in the serum of CKD patients stages 4 and 5 and not in normal subjects has been recently reported [54, 58, 59] . This BSAP isoform is named B1x and it was found in 21 patients (53%) who had lower median levels of BSAP, bone/intestine, B1, B2, and iPTH (49 versus 287 pg/ mL), compared with patients without B1x (P < 0.001). Thirteen patients (65%) with low bone turnover and 8 patients (40%) with non-low bone turnover (P < 0.2) had detectable B1x. Interestingly, B1x was the only biochemical parameter that inversely correlated with histomorphometric parameters of osteoblastic number and activity, indicating bone turnover [54] . Receiver operating characteristic curves showed that B1x could be used for the diagnosis of low bone turnover (area under the curve [AUC], 0.83), whereas BASP (AUC, 0.89) and iPTH (AUC, 0.85) were useful for the diagnosis of non-low-turnover-bone disease [54] . The conclusion of this study is that B1x, BSAP as well as iPTH have similar diagnostic accuracy in distinguishing low from non-low Fig. 3 The effect of renal failure and dietary phosphorus on the calcemic response to PTH in rats. Serum calcium concentration after a constant PTH infusion (Alzet pump) is shown for each of the threee dietary groups (high, modetate and low phosphorus diet), and for the different levels of renal function (normal, moderate and advanced renal failure). During the PTH infusion all rats received a calcium-free, very low phosphorus diet (0.16%). Adapted from reference [26, 27] bone turnover; additionally, the presence of B1x was diagnostic of low bone turnover, whereas elevated BSAP and iPTH levels were useful for the diagnosis of non-low turnover bone disease. It is necessary to emphasize that this study was performed in a small number of participants and the original results need to be confirmed since the B1x isoform utility has not been clearly clarified in clinical grounds. It is noteworthy that B1x needs high-performance liquid chromatography methods for its measurement [54] . Calcifying human aortic vascular smooth muscle cells express the four known BSAP isoforms and B/I, B1X, and B2 seem to play different biological functions during calcification [60] .
Finally, increased BSAP and low iPTH levels are also a potential clinical situation ( Table 2) . Extra-skeletal synthesis of BSAP, the presence of P-Ca-Urea in the media, PTH-independent osteoblast activity (i.e., IL1-, IL6-, IL10-, TNF-mediated), cross-reactivity among different APs (16% for total AP) may explain these observations. In fact, Jean et al. have shown that, in CKD-5D patients with chronic liver disease, serum BSAP levels are not a more useful biomarker of bone turnover than total AP owing to its cross-reactivity with total AP, even when the BASP/total AP ratio is used [61] . Lastly, the potential presence of aluminum overload, osteomalacia, Paget's disease, or lytic bone lesions could explain in some circumstances the discrepancies between BSAP and iPTH [62] .
Association of APs and Survival
Total AP has been associated with inflammation (high serum C-reactive protein), hospitalization rates, and allcause/or cardiovascular mortality, even adjusted to hepatic function [63] [64] [65] [66] [67] . This association has been described in pre-dialysis CKD, hemodialysis (across all ages but especially in young patients), peritoneal dialysis, and transplant patients (pre-transplant values) [19, [68] [69] [70] [71] [72] [73] [74] [75] [76] . It has also been reported in diverse races such as AfricanAmerican or Japanese populations, and among survivors of myocardial infarction and in the general population [19, 70, 71, [77] [78] [79] . Total AP has also been associated with increased coronary artery calcification, incident peripheral arterial disease, vascular stiffening, and sudden cardiac death (APs, regardless of source, ultimately promote vascular calcification) [80, 81] . Total AP has been associated with worsening bone mineral density, higher hip fracture events and worse responsiveness to erythropoiesis stimulating factors [79, [82] [83] [84] . Higher pre-dialysis serum AP levels were independently associated with higher dialysis mortality risk [76] . Compared with patients in the lowest AP quartile (< 66 U/L), those in the highest quartile (≥ 111.1 U/L) had multivariable-adjusted hazard/subhazard ratios (95% confidence interval) of 1.42 (1.34-1.51), 1.43 (1.09-1.88) and 1.39 (1.09-1.78) for all-cause, cardiovascular and infection-related mortality, respectively [76] . On the other hand, hemodialysis patients with pre-transplant serum AP > 120 U/L had also unfavorable post-transplant mortality not observed by iPTH or serum Ca levels [70] .
Importantly, an incremental and linear relationship between higher total AP (> 120 U/L) and all-cause death hazard ratio was described first in hemodialysis patients [66, 85] , as opposed to the U-shaped curve describing the relationship between iPTH and mortality (both high and low iPTH are associated with higher death risk) [66, 72, [85] [86] [87] [88] (Fig. 4) . These findings are described in "fully" adjusted models, using baseline, non-time dependent, time-averaged or time-varying analyses in different dialysis populations, including peritoneal dialysis and non-dialysis dependent CKD patients [66, 72, [86] [87] [88] . Consequently, it has been postulated that total AP may be better than iPTH as a marker of cardiovascular and bone disease [19, 89] .
These incremental and linear association between higher serum total AP levels and higher mortality may additionally provide important clinical information for the management and achievement of beneficial clinical goals in these patients. Since total AP but not BSAP has been as frequently associated with inflammation and mortality in representative samples (i.e., the 1999-2004 National Health and Nutrition Examination Survey (n = 10,707) [65] , it would seem that bone disease would unlikely account for these associations and the discrepancy between total AP and BSAP. Low number of deaths, low statistical power, and CKD with only minor decreases of glomerular filtration rate could have played a role, but intermittent or chronic neutrophil activation or the presence of subclinical hepatic disease have been suggested as potential causal mechanisms. In fact, BSAP was indeed a predictor of mortality in both CKD and dialysis patients in other studies [74, 90] . Not surprisingly, no uniform or weaker associations with mortality, vascular calcification, bone mineral density or long-term hip fracture risk have also been reported for both APs [84, 91, 92] .
Of note, the direct association of AP levels with mortality persists in different iPTH strata, even including iPTH < 150 pg/ml (< 2X ULN) [66, 85] . Thus, low APs have been associated with greater survival, questioning the widely accepted concept that low-turnover-bone disease (i.e., adynamic bone disease) increases mortality. Nevertheless, some time-averaged measurements did not show lower risk of death in the lowest AP categories (maybe because fractures, vascular calcification, or associated hypercalcemia mitigate the potential benefits). For instance, a study including 407 unselected European CKD-5D subjects showed a statistically significant association between total AP with crude mortality and also a stronger death risk association of total AP and individual lowest skeletal BSAP with crude mortality [93] . Finally, associations of change of total AP and all-cause 6-month mortality have also recently been described in a huge cohort of 102,754 incident hemodialysis patients [94] .
APs and Vascular Calcification
It is well known that the process of vascular calcification involves chondro-osteoblastic conversion of vascular smooth muscle cells (VSMCs), evidenced by the loss of VSMC markers (such as α-actin) and the novo expression of osteoblast markers (TNAP, osteocalcin, osteopontin) or osteocyte markers such as sclerostin and podoplanin [95] [96] [97] [98] [99] . All BSAP isoforms, including B1x, are also expressed in vascular smooth muscle cells (Fig. 2) , the calcification of which is associated with a strong increase in BSAP activity level [60, 100] . Experimental studies also illustrate the key role played by TNAP in the process of arterial mineralization. A mouse model overexpressing human TNAP in VSMCs and in endothelial cells shows extensive vascular calcification, hypertension, and shortened lifespan [101, 102] . Treatment of these animals with a TNAP inhibitor (SBI-425) significantly reduced vascular calcifications and improved survival [101] . Interestingly, in patients with hyperphosphatasia, a group of disorders that feature elevated serum TNAP activity (i.e., Paget's disease of bone), there is no clear evidence for an association with vascular calcification [103] . This may indicate that only membrane-bound TNAP plays a role in vascular calcification, or that other vascular-specific cofactors are necessary to induce vascular calcification in the context of elevated TNAP [103] . One such component was postulated to be collagen I expression by osteoblasts [103] [104] [105] .
Frequent associations between AP or BSAP levels and vascular calcification have been reported not only in CKD but also in osteoporotic patients [106, 107] . Consequently, as it will be emphasized later, it has been suggested that not only pyrophosphate or phytate (another endogenous crystallization inhibitor) but also inhibitors of alkaline phosphatase could potentially prevent, attenuate or reverse the progression of VSMC calcification [2, [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] . However, it is important to note that these strategies may interfere with normal bone formation. Therefore, APs may have both friends and foes action on bone and mineral homeostasis since, at one point, APs provide phosphate in order to improve bone mineralization but APs may induce vascular calcification and consequently increase cardiovascular morbidity and mortality, especially in CKD and hyperphosphatemic patients. Independent actions on vessels and bone have been described [101, 110] .
Another possible link between total AP or BSAP and mortality comes from the recognition that TNAP stimulates hydrolysis of pyrophosphate, and thus high levels of circulating TNAP or TNAP locally produced by calcifying VSMCs could lower pyrophosphate concentrations, thus favoring vascular calcification [2] (Fig. 2) . APs are also speculated to inactivate the calcification inhibitor osteopontin through dephosphorylation [19, 118] . On the other hand, matrix Gla protein (MGP)-a well-known inhibitor of vascular mineralization-may indirectly reduce AP activity by inhibiting bone morphometric protein-2 induction of AP [119, 120] . It has also recently been described that FGF23 is a suppressor of TNAP gene expression via a klotho-independent, FGF receptor-(FGFR3)-mediated signaling axis in osteoblasts, Fig. 4 Different relationship (U-shape vs linear) between serum total alkaline phosphatase and intact PTH quartiles and all-cause death hazard ratio leading to inhibition of mineralization through accumulation of the TNAP substrate pyrophosphate and decreased local inorganic free P [121, 122] . Due to the increased activity of TNAP and elevated levels of inorganic P in the failing heart compared with the normal heart, upstream regulators of TNAP such as secreted Frizzle-related protein 2 (sFRP2) have been associated with cardiac fibro-calcification [123] . Furthermore, TNAP seems to favor intracellular deposition of lipids in pre-adipocytes (124), a mechanism that in VSMCs could be additive for calcifications [125] , and BASP or intestinal AP levels also correlate with parameters of glucose metabolism and of metabolic syndrome, further increasing links with vascular calcification and survival [126] [127] [128] . Finally, higher APs levels are also associated with lower calcidiol levels [129, 130] , which are in turn associated with increased mortality per se [131] . A recent review on the mechanisms associating AP activity, vascular calcification, inflammation, endothelial dysfunction, cardiovascular disease, and survival has been recently published [19] .
Pharmacology and Genetics
In addition to classical treatments which affect bone formation rate and thus indirectly decrease AP's levels (i.e., vitamin D derivatives and calcimimetics) [132] [133] [134] [135] , several manoeuvers are currently underway attempting either to directly or indirectly influence pyrophosphate deficiency or regulate the activity of TNAP's. Whereas plasma pyrophosphate is reduced in hemodialysis patients and it is cleared by dialysis [136] , AP is neither dialyzable nor filterable by the normal kidney, although it is possible that with convective and very high-flux hemodialysis or hemofiltration plasma AP levels could slightly decrease [137] . Thus, TNAP evolved as a druggable target for the treatment and/or prevention of VSMC calcification [2, 112] . As such, phytate in the form of the hexasodium salt SNF472 is currently being developed for the treatment of calciphylaxis and cardiovascular calcification in hemodialysis patients [138] [139] [140] . The activity of several related transporters and enzymes discovered from genetic diseases associated with severe vascular calcification are also currently under scrutiny. Thus, ABCC6 is an efflux transporter primarily expressed in liver which facilitates the release of adenosine triphosphate (ATP) from hepatocytes. Within the liver vasculature, ATP is converted into pyrophosphate and thus liver ABCC6-mediated ATP secretion seems to be the main source of pyrophosphate in the systemic circulation [141] . The chemical chaperone 4-phenylbutyrate (4-PBA) seems a promising strategy for allele-specific therapy of ABCC6-associated calcification disorders [142] . ENPP1 -Fc fusion proteins seem to prevent mortality and vascular calcifications in a rodent model of generalized arterial calcification of infancy (GACI) [143] .
ANK is also a nonenzymatic plasma-membrane pyrophosphate channel that supports pyrophosphate levels (Fig. 1 ) [144] [145] [146] . Of note, pyrophosphate treatment also ameliorates a mouse model of Hutchinson-Gilford progeria syndrome, in which excessive vascular calcification is caused by reduced extracellular accumulation of pyrophosphate that results from increased TNAP activity and diminished ATP availability caused my mitochondrial dysfunction in VSMC [147] . Interestingly, in the field of nephrology, peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in an experimental model in mice [148] . On the other hand, benzofuran derivatives and other compounds such as SBI-425 mentioned earlier seem to selectively inhibit TNAP [101, [112] [113] [114] [115] 149] . This latter compound seems to inhibit vascular calcification without a negative effect on bone mineralization [101] . Apabetalone (RVX-208), a BET (bromodomain and extraterminal)-motif inhibitor, modulates the epigenetic regulation of several genes [150] , repressing new pathways that contribute to cardiovascular disease [151] . Interestingly, apabetalone reduces circulating levels of APs, which was associated with a marked reduction of major cardiovascular events [152, 153] . A large phase III study of this compound for the prevention of cardiovascular complications in type II diabetes is ongoing [154] .
AP Targeting in Other Clinical Conditions
Systemic administration of APs (bovine intestinal AP, human placental AP, recombinant or soluble non-targeted chimeric APs) can exert nephroprotective and anti-inflammatory effects in sepsis and after cardiac surgery [19, 155, 156] . Dephosphorylation and thereby detoxification of detrimental molecules involved in the pathogenesis of sepsisassociated AKI [i.e., endotoxins like di-phosphoryl lipopolysaccharide from the cell wall of Gram-negative bacteria or nucleotides like ATP, a pro-inflammatory mediator released during cellular stress, which can be converted by AP (ATPase activity) into the tissue-protective and anti-inflammatory molecule adenosine] seem to be responsible for this protective effect [157, 158] . Further clinical studies are needed to elucidate whether intestinal APs could prevent and combat systemic and intestinal inflammation or dysbiosis, and/or metabolic syndrome [19] . Traditional herbal remedies like curcumin, which increases the expression of intestinal APs, have been shown to correct gut permeability in CKD [159] and inhibit manifestations of metabolic syndrome [160] .
On the other hand, hypophosphatasia (HPP) is a rare hereditary metabolic disorder caused by inactivating mutations in ALPL [161] . Although these patients often have hyperphosphatemia and hypercalcemia, this disease is not associated with accelerated vascular calcification [19, 161] . Enzyme replacement therapy with asfotase-α, a recombinant mineral-targeted human TNAP, has resulted in dramatic improvements in bone mineralization and survival [19] . However, long-term administration or managing HPP in adults, especially in the presence of hyperphosphatemia, could theoretically promote vascular calcification and cardiovascular complications [19, 161] .
Conclusion
Considering that the biological variation of BSAP is less than half that reported for iPTH, the APs assays have been judged to be more reliable for diagnostic (bone disease) and prognostic (clinical outcomes) purposes [162] . Thus, the use of APs as an alternative marker or target goal for bone mineral metabolism and cardiovascular disease in the setting of CKD-MBD has been underlined [9, 19, 163] . However, costs, availability, former clinical experience, and the lack of studies or clear-cut targets using APs as a primary therapeutic goal for significant outcomes still represent significant strengths for the iPTH assay [164] , and consequently guidelines still recommend frequent measurement of iPTH in order to determine PTH trends to implement the appropriate therapy. The additional information provided by APs, with a much lower intraindividual coefficient of variation, should also be taken into account [162, 165] . Despite we lack prospective data demonstrating that lowering APs would alter fracture or mortality outcomes, the diagnostic potential of APs in the management of renal osteodystrophy should not be forgotten, notwithstanding the major gap for these recommendations in current guidelines [8] . Moreover, the additional information provided by APs on survival should be definitely underlined in clinical grounds, whereas their narrow relationship with vascular calcification, cardiovascular disease, and mortality results in further investigation for the development of novel therapeutic approaches, not only for CKD but also for sepsis, AKI, metabolic syndrome, diabetes, or aging. 
